Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	205.9	82.55	48.34	25.71
Cash & Cash Equivalents	205.9	82.55	48.34	25.71
Cash Growth	325.90%	70.75%	88.07%	-
Receivables	0	0.01	0.33	1.5
Other Current Assets	2.42	2.84	0.54	0.48
Total Current Assets	208.31	85.39	49.22	27.68
Property, Plant & Equipment	1.55	1.11	1.17	1.06
Other Long-Term Assets	0.06	0.13	0.46	0.05
Total Long-Term Assets	1.61	1.24	1.63	1.11
Total Assets	209.92	86.63	50.85	28.79
Accounts Payable	2.41	1.07	1.61	0.6
Current Debt	1.15	0	0	0
Other Current Liabilities	4.45	4.54	3.95	1.21
Total Current Liabilities	8.01	5.61	5.56	1.81
Long-Term Debt	8.81	9.86	9.47	0
Other Long-Term Liabilities	0	1.35	2	1.3
Total Long-Term Liabilities	8.81	11.21	11.47	1.3
Total Liabilities	16.82	16.82	17.03	3.11
Total Debt	9.96	9.86	9.47	0
Debt Growth	5.22%	4.18%	-	-
Retained Earnings	-90.38	-76.97	-40.66	-12.95
Comprehensive Income	-0.08	-0.08	-0.05	-0.02
Shareholders' Equity	193.1	-71.67	-38.41	-12.48
Net Cash / Debt	195.94	72.69	38.88	25.71
Net Cash / Debt Growth	403.96%	86.96%	51.25%	-
Net Cash Per Share	-	19.48	11.28	4.79
Working Capital	200.3	79.78	43.66	25.87
Book Value Per Share	10.97	-19.21	-11.14	-2.33

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).